HBM Healthcare Investments Aktie
WKN: 984345 / ISIN: CH0012627250
18.05.2022 06:46:05
|
Publication of Annual Report 2021/2022 and Invitation to the Ordinary Shareholders Meeting
HBM Healthcare Investments AG / Key word(s): Annual Results The invitation to the 21st Ordinary Shareholders Meeting on 10 June 2022 has been sent to the shareholders of HBM Healthcare Investments today. In accordance with the Ordinance on Measures to Combat the Coronavirus, issued by the Swiss Federal Council, the shareholders are not permitted to participate in person. All shareholders are kindly asked to exercise their rights exclusively through the independent proxy by way of written or electronic instruction and power of attorney. The detailed invitation with all motions of the Board of Directors is displayed on the Companys website www.hbmhealthcare.com/en/investors/shareholders-meeting. Agenda for the 21st Ordinary Shareholders Meeting on 10 June 2022
HBM Healthcare Investments also published today its Annual Report 2021/2022 on the Companys website www.hbmhealthcare.com/en/investors/financial-reports. Contact End of ad hoc announcement |
Language: | English |
Company: | HBM Healthcare Investments AG |
Bundesplatz 1 | |
6300 Zug | |
Switzerland | |
Phone: | +41438887171 |
Fax: | +41438887172 |
E-mail: | info@hbmhealthcare.com |
Internet: | https://www.hbmhealthcare.com |
ISIN: | CH0012627250 |
Valor: | 1262725 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1355041 |
End of Announcement | EQS News Service |
|
1355041 18-May-2022 CET/CEST

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu HBM Healthcare Investments AGmehr Nachrichten
16.04.25 |
Key Figures 15.04.2025 (EQS Group) | |
01.04.25 |
HBM Healthcare Investments expects to report a net profit of CHF 19 million for the 2024/2025 financial year (EQS Group) | |
01.04.25 |
HBM Healthcare Investments erwartet Jahresgewinn von CHF 19 Millionen für das Geschäftsjahr 2024/2025 (EQS Group) | |
01.04.25 |
Key Figures 31.03.2025 (EQS Group) | |
20.03.25 |
Sanofi erwirbt DR-0201, ein klinisches Programm des HBM-Portfolio-Unternehmens Dren Bio, für einen Vorabbetrag von USD 600 Millionen, zuzüglich möglicher Meilensteine (EQS Group) | |
20.03.25 |
Sanofi to acquire DR-0201, a clinical-stage program of HBM portfolio company Dren Bio, for upfront amount of USD 600 million, plus potential milestones (EQS Group) | |
17.03.25 |
Key Figures 15.03.2025 (EQS Group) | |
03.03.25 |
Key Figures 28.02.2025 (EQS Group) |
Analysen zu HBM Healthcare Investments AGmehr Analysen
Aktien in diesem Artikel
HBM Healthcare Investments AG | 164,00 | 0,61% |
|